Difficulty: Medium
Average Score: 80%
Practice
Which of the following drugs is MOST likely to cause hypoglycemia when used as monotherapy in the treatment of type 2 diabetes?
Correct answer
B
Rationale
In the context of CNS pharmacology and the treatment of type 2 diabetes, the correct answer to the question is option B) Glyburide. Glyburide belongs to the class of sulfonylureas, which work by stimulating insulin release from the pancreas. This mechanism can lead to an increased risk of hypoglycemia, especially when used as monotherapy without considering the patient's individual response.
Option A) Acarbose is an alpha-glucosidase inhibitor that does not directly affect insulin levels and is less likely to cause hypoglycemia as compared to sulfonylureas like glyburide.
Option C) Metformin is a biguanide that primarily works by decreasing hepatic glucose production and improving insulin sensitivity. It does not typically cause hypoglycemia as a side effect.
Option D) Rosiglitazone is a thiazolidinedione that improves insulin sensitivity in peripheral tissues but does not directly stimulate insulin secretion, making it less likely to cause hypoglycemia compared to sulfonylureas.
In an educational context, understanding the mechanisms of action of different antidiabetic drugs is crucial for healthcare professionals to make informed decisions regarding their prescription. Knowledge of the side effect profiles of these medications, including the risk of hypoglycemia, is essential for safe and effective diabetes management. Students and practitioners must be able to differentiate between drug classes and their associated risks to provide optimal care to patients with diabetes.
Option A) Acarbose is an alpha-glucosidase inhibitor that does not directly affect insulin levels and is less likely to cause hypoglycemia as compared to sulfonylureas like glyburide.
Option C) Metformin is a biguanide that primarily works by decreasing hepatic glucose production and improving insulin sensitivity. It does not typically cause hypoglycemia as a side effect.
Option D) Rosiglitazone is a thiazolidinedione that improves insulin sensitivity in peripheral tissues but does not directly stimulate insulin secretion, making it less likely to cause hypoglycemia compared to sulfonylureas.
In an educational context, understanding the mechanisms of action of different antidiabetic drugs is crucial for healthcare professionals to make informed decisions regarding their prescription. Knowledge of the side effect profiles of these medications, including the risk of hypoglycemia, is essential for safe and effective diabetes management. Students and practitioners must be able to differentiate between drug classes and their associated risks to provide optimal care to patients with diabetes.